2023

1. Biomarkers for immunotherapy in non-small cell lung cancer: a current and future reality

   Precision Cancer Medicine

2. Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data

   Cancers, Vol. 15, Núm. 17

3. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis

   Chinese Clinical Oncology, Vol. 12, Núm. 6